Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of WGI-0301 alone and with sorafenib in advanced hepatocellular carcinoma
CTR20242426Phase 2Active
- Sponsor
- Haichang Biotech
- Start
- Aug 2024
- Modality
- Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of WGI-0301, sorafenib in hepatocellular carcinoma (HCC), sponsored by Haichang Biotech. Started Aug 2024; status: active.
02
Drugs
WGI-0301sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20242426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242426.